{"product_id":"ivd-quality-control-market-by-offering-product-serum-blood-urine-based-data-management-service-technology-biochemistry-molecular-immunoassay-hematology-application-infectious-diseases-oncology-cardiology-and-end-user-global-forecast","title":"IVD Quality Control Market by Offering (Product [Serum, Blood, Urine-based], Data Management, Service), Technology (Biochemistry, Molecular, Immunoassay, Hematology), Application (Infectious Diseases, Oncology, Cardiology), and End User – Global Forecast","description":"\u003cp\u003eIVD Quality Control Market by Offering (Product [Serum, Blood, Urine-based], Data Management, Service), Technology (Biochemistry, Molecular, Immunoassay, Hematology), Application (Infectious Diseases, Oncology, Cardiology), and End User–Global Forecast to 2030\u003cbr\u003e\nThe IVD quality control market is expected to reach $2.19 billion by 2030, at a CAGR of 4.3% from 2023 to 2030.\u003c\/p\u003e\n\n\u003cp\u003eAfter extensive primary and secondary research, the report provides an in-depth analysis of the IVD quality control market. The report also provides insights into the key drivers, restraints, challenges, and opportunities in the IVD quality control market. The growth of the IVD quality control market is driven by the rising prevalence of chronic diseases, coupled with the increasing geriatric population, growing demand for third-party quality controls, need for internal and external quality assessment reports, increasing number of clinical laboratories, growing demand for Point-of-Care (POC) and rapid diagnostics. However, stringent technical requirements and regulatory processes for quality controls restrain this market's growth.\u003c\/p\u003e\n\n\u003cp\u003eThe growing demand for multi-analyte and multi-instrument controls offers opportunities for market growth. However, the evolving regulatory landscape and lack of access to quality control\/quality assurance materials are the major challenges to market growth.\u003c\/p\u003e\n\n\u003cp\u003eAmong the offering, in 2023, the quality control products segment is estimated to account for the largest share of the IVD quality control market. Increasing adoption of diagnostic products, demand for external quality assessment programs as these programs use quality controls in their programs, development of multi-analyte quality controls, new product launches, and increasing demand for independent controls contribute to the segments’ largest share.\u003c\/p\u003e\n\n\u003cp\u003eAmong the technologies, in 2023, the immunoassay\/immunochemistry segment is estimated to account for the largest share of the IVD quality control market. The growing prevalence of chronic and infectious diseases and the increased adoption of immunoassay\/immunochemistry tests, technological innovations in these tests, and the simultaneous development of quality control contributed to the segment's largest share.\u003c\/p\u003e\n\n\u003cp\u003eAmong the application, in 2023, the infectious diseases segment is estimated to account for the largest share of the IVD quality control market. The increasing prevalence of infectious diseases has led to the availability of a broad range of quality controls that are designed to monitor the assay precision of IVD tests for infectious diseases such as hepatitis, retrovirus, sexually transmitted diseases, congenital diseases, and other infectious diseases. According to the WHO, in 2020, there were an estimated 376 million new cases of sexually transmitted infections (STIs) worldwide, with chlamydia accounting for 129 million, gonorrhea for 82 million, syphilis for 7.1 million, and trichomoniasis for 156 million of the reported cases. The need for diagnosis of such infectious diseases also required quality controls for the quality assessment of tests, which further supported the largest share of the segment.\u003c\/p\u003e\n\n\u003cp\u003eAmong the end users, in 2023, the hospitals \u0026amp; clinics segment is estimated to account for the largest share of the IVD quality control market. The large segment share is majorly attributed to the large volume of diagnostics tests carried out in the hospitals, the rising prevalence of healthcare-associated infections (HAIs), increasing healthcare expenditure, and the rising number of hospitals and clinics across emerging markets.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of the geographical scenario of the IVD quality control market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, the Middle East \u0026amp; Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD quality control market, followed by Europe, Asia-Pacific, Latin America, and the Middle East \u0026amp; Africa. The high prevalence of chronic and infectious diseases, increasing awareness regarding early disease diagnosis, growing adoption of advanced diagnostic products, and increasing funding activities, coupled with novel developments in diagnostic technologies, are the factors supporting the largest share of this market.\u003c\/p\u003e\n\n\u003cp\u003eThe key players operating in the IVD quality control market are Seimens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), LGC Group (U.K.), Thermo Fisher Scientific Inc. (U.S.), SERO AS (Norway), Randox Laboratories Ltd. (U.K.), QuidelOrtho Corporation (U.S.), Streck LLC (U.S.), Microbiologics, Inc. (U.S.), and Bio-Techne Corporation (U.S.)\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report:\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market Assessment - by Offering\u003c\/p\u003e\n\n\u003cp\u003eQuality Control Products\u003cbr\u003e\nQuality Control Products, by Type\u003cbr\u003e\nSerum\/Plasma-based Controls\u003cbr\u003e\nWhole Blood-based Controls\u003cbr\u003e\nUrine-based Controls\u003cbr\u003e\nOther Controls\u003cbr\u003e\nQuality Control Products, by Function\u003cbr\u003e\nIndependent Controls\u003cbr\u003e\nInstrument-Specific Controls\u003cbr\u003e\nQuality Assessment Services\u003cbr\u003e\nData Management Solutions\u003c\/p\u003e\n\n\u003cp\u003eNotes: Other controls include saliva-based controls, cerebrospinal fluid-based, and protein controls.\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market Assessment - by Technology\u003c\/p\u003e\n\n\u003cp\u003eImmunoassay\/Immunochemistry\u003cbr\u003e\nBiochemistry\/Clinical Chemistry\u003cbr\u003e\nMolecular Diagnostics\u003cbr\u003e\nHematology\u003cbr\u003e\nCoagulation\/Hemostasis\u003cbr\u003e\nMicrobiology\u003cbr\u003e\nOther Technologies\u003c\/p\u003e\n\n\u003cp\u003eNotes:Other technologies include histochemistry, urinalysis, and whole-blood glucose monitoring\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market Assessment - by Application\u003c\/p\u003e\n\n\u003cp\u003eInfectious Diseases\u003cbr\u003e\nOncology\u003cbr\u003e\nCardiology\u003cbr\u003e\nAutoimmune Disorders\u003cbr\u003e\nNeurology\u003cbr\u003e\nOther Applications\u003c\/p\u003e\n\n\u003cp\u003eNotes:Other applications include pregnancy and fertility testing, drug abuse testing, diabetes, genetic disorders, and trace elements testing\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market Assessment - by End User\u003c\/p\u003e\n\n\u003cp\u003eHospitals \u0026amp; Clinics\u003cbr\u003e\nDiagnostic Laboratories\u003cbr\u003e\nAcademic Institutes \u0026amp; Research Laboratories\u003cbr\u003e\nOther End Users\u003c\/p\u003e\n\n\u003cp\u003eNotes:Other end users include home care, nursing homes, ambulatory care centers, and transfusion laboratories.\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market Assessment - by Geography\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nU.K.\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\nAsia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nIndia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of Latin America\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eIVD Quality Control Market - Global Opportunity Analysis and Industry Forecast (2023–2030)  - Report SummaryReport MetricsDetailsYears Considered2021 - 2030Base Year2022Forecast Period2023-2030Page Count267Units ReferencedValue (USD Million)Segments\/Key TopicsMarket by Offering, Technology, Application, and End UserRegions CoveredNorth America, Europe, Asia-Pacific, Latin America, Middle East \u0026amp; AfricaKey Companies MentionedSiemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), LGC Group (U.K.), Thermo Fisher Scientific Inc. (U.S.), SERO AS (Norway), Randox Laboratories Ltd. (U.K.), QuidelOrtho Corporation (U.S.), Streck LLC (U.S.), Microbiologics, Inc. (U.S.), and Bio-Techne Corporation (U.S.)\u003c\/p\u003e\n\n\u003cp\u003eFAQs About the Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus of the IVD quality control market study?\u003c\/p\u003e\n\n\u003cp\u003eThis study covers quality control products, quality assessment services, and data management solutions applied in hospitals \u0026amp; clinics, diagnostic laboratories, academic institutes \u0026amp; research laboratories, and other end users.\u003c\/p\u003e\n\n\u003cp\u003eWhat is the revenue generated from the sales of IVD quality control products \u0026amp; services? At what rate is their demand expected to grow for the next 5-7 years?\u003c\/p\u003e\n\n\u003cp\u003eThe IVD quality control market is projected to reach $2.19 billion by 2030, at a CAGR of 4.3% during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eWhich offering is expected to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eBased on offering, in 2023, the quality control products segment is expected to account for the largest share of the IVD quality control market. Development of multi-analyte quality controls and new product launches contribute to the segment’s largest share.\u003c\/p\u003e\n\n\u003cp\u003eWhich technology segment is expected to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eBased on technology, in 2023, the immunoassay\/immunochemistry segment is expected to account for the largest share of the IVD quality control market. The growing number of immunoassay\/immunochemistry tests, as they provide rapid, convenient, and accurate results for the detection and quantitation of targets and continuous development of new biomarkers, contribute to the segment’s largest share.\u003c\/p\u003e\n\n\u003cp\u003eWhich application segment is expected to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eBased on application, in 2023, the infectious diseases segment is expected to account for the largest share of the IVD quality control market. The rising prevalence of infectious diseases and government initiatives to promote awareness and testing of these infectious diseases contribute to the segment’s largest share.\u003c\/p\u003e\n\n\u003cp\u003eWhich end user segment is expected to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, in 2023, the hospitals \u0026amp; clinics segment is expected to account for the largest share of the IVD quality control market. The expansion of hospitals, the increasing number of patients visiting the hospitals \u0026amp; clinics, and the collaborations between hospitals and government organizations for screening programs support the segment’s largest share.\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the IVD quality control market?\u003c\/p\u003e\n\n\u003cp\u003eThe rising prevalence of chronic diseases, coupled with the increasing geriatric population, growing demand for third-party quality controls, need for internal and external quality assessment reports, increasing number of clinical laboratories, growing demand for Point-of-Care (POC) and rapid diagnostics are some of the factors driving the growth of this market. Additionally, the growing demand for multi-analyte and multi-instrument controls offers opportunities for market growth.\u003c\/p\u003e\n\n\u003cp\u003eWho are the major players operating in the IVD quality control market?\u003c\/p\u003e\n\n\u003cp\u003eKey companies operating in the IVD quality control market are Seimens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), LGC Group (U.K.), Thermo Fisher Scientific Inc. (U.S.), SERO AS (Norway), Randox Laboratories Ltd. (U.K.), QuidelOrtho Corporation (U.S.), Streck LLC (U.S.), Microbiologics, Inc. (U.S.), and Bio-Techne Corporation (U.S.)\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 267 Pages \/ MCW16238184","offer_id":47652851450162,"sku":null,"price":5010.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/ivd-quality-control-market-by-offering-product-serum-blood-urine-based-data-management-service-technology-biochemistry-molecular-immunoassay-hematology-application-infectious-diseases-oncology-cardiology-and-end-user-global-forecast","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}